title: Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala.
abstract: The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPARgamma(2)) is associated with reduced risk for type 2 diabetes. Although increased insulin sensitivity of glucose disposal and lipolysis has been reported, the exact mechanism by which the risk reduction is conferred is not clear. Because the conclusion of greater insulin sensitivity hinged upon lower insulin levels in some studies, it is possible that more efficient insulin clearance is involved. We therefore estimated insulin clearance during a euglycemic hyperinsulinemic clamp (insulin infusion rate divided by steady-state insulin concentration, 229 normal glucose tolerant [NGT] subjects), an oral glucose tolerance test (OGTT) (mean C-peptide divided by mean insulin concentrations, 406 NGT, 54 impaired glucose tolerant or mildly diabetic subjects), and a hyperglycemic clamp (120 minutes, 10 mmol/L, C-peptide divided by insulin in the steady-state, 56 NGT subjects). In the carriers of the Ala allele (prevalence approximately 24%), insulin clearance in all 3 protocols was significantly greater ( approximately 10%), than in controls. While the results from the euglycemic clamp reflect both hepatic and peripheral insulin clearance, those from the OGTT and the hyperglycemic clamp reflect mainly hepatic insulin extraction. Free fatty acids (FFA) during the steady state of the euglycemic hyperinsulinemic clamp were significantly lower in carriers of the Ala allele (26 +/- 5 micromol/L) than in controls (46 +/- 3 micromol/L, P =.02). In conclusion, the Pro12Ala polymorphism is associated with increased insulin clearance. This could be the result of reduced FFA delivery, which has been shown to improve hepatic insulin removal and sensitivity. Because PPARgamma(2) is mainly expressed in adipose tissue, one of the main regulatory effects of the polymorphism may well be the more efficient suppression of (possibly intra-abdominal) lipolysis.
authors.affiliation: Medizinische Klinik, Abteilung für Endokrinologie, Stoffwechsel und Pathobiochemie, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
authors.forename: Otto
authors.initials: O
authors.lastname: Tschritter
authors.forename: Andreas
authors.initials: A
authors.lastname: Fritsche
authors.forename: Norbert
authors.initials: N
authors.lastname: Stefan
authors.forename: Michael
authors.initials: M
authors.lastname: Haap
authors.forename: Claus
authors.initials: C
authors.lastname: Thamer
authors.forename: Oliver
authors.initials: O
authors.lastname: Bachmann
authors.forename: Dominik
authors.initials: D
authors.lastname: Dahl
authors.forename: Elke
authors.initials: E
authors.lastname: Maerker
authors.forename: Anna
authors.initials: A
authors.lastname: Teigeler
authors.forename: Fausto
authors.initials: F
authors.lastname: Machicao
authors.forename: Hans
authors.initials: H
authors.lastname: Häring
authors.forename: Michael
authors.initials: M
authors.lastname: Stumvoll
mesh_terms: D000328:Adult; D000409:Alanine; D000483:Alleles; D002096:C-Peptide / Q000378:metabolism; D005260:Female; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D008297:Male; D011110:Polymorphism, Genetic / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000502:physiology*; D014157:Transcription Factors / Q000235:genetics / Q000502:physiology*
chemical_list: D002096:C-Peptide; D007328:Insulin; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D000409:Alanine